Management of Type 2 Diabetes Complications – Evidence‑Based Recommendations

Microvascular Complications

Diabetic Retinopathy

• Intensive glycemic control targeting an A1C ≈ 7 % reduces the incidence and progression of diabetic retinopathy by ~25 % compared with conventional treatment (American Diabetes Association) 1.
• The relationship between glucose level and retinopathy risk is continuous and log‑linear, extending into the normal A1C range without a clear threshold (American Diabetes Association) 1.
• All individuals with diabetes should receive a comprehensive dilated eye examination by an ophthalmologist or optometrist experienced in diabetic eye disease at least once per year (American Society of Nephrology) 3.
• Anti‑VEGF agents are now the first‑line therapy for diabetic macular edema, typically administered near‑monthly intravitreally during the first year (American Diabetes Association) 4.
• Tight blood‑pressure control and fenofibrate therapy in dyslipidaemic patients can further slow retinopathy progression (American Diabetes Association) 4.

Diabetic Kidney Disease (DKD)

• Approximately 40 % of adults with type 2 diabetes develop DKD, defined by persistent albuminuria (UACR > 30 mg/g) or eGFR < 60 mL/min/1.73 m² for ≥ 3 months (American Society of Nephrology) 5.
• Target blood pressure should be < 130/80 mmHg in patients with diabetes and CKD stages 1‑4 (American Society of Nephrology) 3, 6.
• ACE inhibitors or ARBs are recommended as first‑line antihypertensive agents, to be combined with a diuretic when needed (American Society of Nephrology) 3.
• SGLT2 inhibitors and GLP‑1 receptor agonists are advised for renal and cardiovascular protection in DKD, independent of glycaemic‑control requirements (Lancet Diabetes & Endocrinology; American Society of Nephrology) 7, 5.
• Annual screening for albuminuria and eGFR is essential for early detection of DKD (American Society of Nephrology) 3.

Diabetic Neuropathy

• Screening for peripheral neuropathy should start at the time of type 2 diabetes diagnosis and be repeated at least annually (American Diabetes Association) 4.
• Recommended assessment includes history, pin‑prick or temperature sensation (small‑fiber), vibration testing with a 128‑Hz tuning fork (large‑fiber), and a 10‑g monofilament test (American Diabetes Association) 4.
• First‑line pharmacologic agents for neuropathic pain are pregabalin, duloxetine, or gabapentin (American Diabetes Association) 4.
• Gastroparesis should be considered in patients with erratic glycaemic control or upper GI symptoms; gastric‑emptying scintigraphy is the diagnostic gold standard (American Diabetes Association) 4.

Foot Complications

• Visual foot inspection at every clinical encounter and a comprehensive foot exam (including monofilament testing and pedal pulse assessment) at least annually are required (American Society of Nephrology) 3.
• Patients at high risk (e.g., CKD, cardiovascular disease, peripheral vascular disease, neuropathy, or diabetes duration > 10 years) should be referred to a foot‑care specialist for preventive care each year (American Society of Nephrology) 3.
• Daily self‑inspection by patients is essential for early ulcer detection (American Society of Nephrology) 3.

Macrovascular Complications

Cardiovascular Disease (CVD)

• CVD is the leading cause of death in people with diabetes, conferring a 2‑ to 4‑fold increased risk (American Diabetes Association) 1.
• Intensive glycaemic control yields modest macrovascular benefit; the UKPDS showed a 16 % reduction in cardiovascular complications with median A1C 7.0 % versus 7.9 % (American Diabetes Association) 1.
• Long‑term follow‑up of the DCCT demonstrated that early intensive control produced a 42 % reduction in cardiovascular outcomes and a 57 % reduction in non‑fatal MI, stroke, or CVD death after 9 years (American Diabetes Association) 1.

Contemporary Cardiovascular Protection

• SGLT2 inhibitors and GLP‑1 receptor agonists provide cardiovascular and renal protection beyond glucose lowering in high‑risk type 2 diabetes patients (Lancet Diabetes & Endocrinology; American Diabetes Association) 7, 8.
• Meta‑analyses confirm that SGLT2 inhibitors reduce major adverse cardiovascular events, with pronounced benefit for heart‑failure prevention (American Diabetes Association) 8.
• These agents should be prescribed irrespective of baseline A1C in patients with established CVD or high cardiovascular risk (Lancet Diabetes & Endocrinology) 7.

Dyslipidaemia Management

• Target LDL‑C < 100 mg/dL in diabetes with CKD stages 1‑4; < 70 mg/dL is an option for very high‑risk individuals (American Society of Nephrology) 6.
• Statin therapy is indicated for patients with diabetes, CKD stages 1‑4, and LDL‑C > 100 mg/dL (American Society of Nephrology) 6.
• Lipid‑lowering therapy is cost‑effective and markedly reduces cardiovascular events in type 2 diabetes with CKD (American Society of Nephrology) 6.

Glycaemic Targets & Management Strategy

• The general A1C goal is < 7 % for most adults with diabetes, balancing microvascular risk reduction against hypoglycaemia risk (American Diabetes Association) 1, 2, 9.
• More stringent A1C targets (6‑7 %) may be appropriate for younger patients with long life expectancy and low hypoglycaemia risk, especially when using agents that do not cause hypoglycaemia (American Diabetes Association) 9.
• Less stringent A1C goals are advisable for patients with advanced complications, limited life expectancy, or high hypoglycaemia risk (American Diabetes Association) 9.
• Early intervention after diagnosis yields durable protection against both micro‑ and macro‑vascular complications (American Diabetes Association) 10.

Screening, Monitoring & Safety

• Self‑monitoring of blood glucose should be performed at least three times daily in patients using multiple insulin injections (American Society of Nephrology) 3.
• HbA1c should be measured at least twice yearly in stable patients meeting goals and approximately every three months when therapy changes or goals are unmet (American Society of Nephrology) 3.
• Orthostatic blood‑pressure measurement is recommended because autonomic neuropathy is common in diabetes and CKD (American Society of Nephrology) 6.
• Intensive glycaemic therapy increases the risk of severe hypoglycaemia approximately three‑fold (DCCT data) (American Diabetes Association) 10.
• Weight gain is a notable adverse effect of intensive insulin regimens and should be monitored (American Diabetes Association) 10.

All statements are derived from peer‑reviewed evidence with the cited reference IDs indicated after each bullet point.